How to use the speech recognition tool?

NCT02671539

THOR

Tübingen Choroideremia gene therapy trial open label Phase 2 clinical trial using an
adeno-associated viral vector (AAV2) encoding Rab-escort protein 1 (REP1)

Type: Interventional



Status of the trial: Completed

Orphan Drug Recognition: Yes

Inclusion

  • Opening Date: 2016-01-11
  • Closing Date: 2016-02-09

Criteria

More information

Children: No

Adults: Yes

Funder Type: other

HCP: Other investigators


Within ERN-EYE members

Principal investigators




Other investigators

Workgroups

  • Retinal Rare Eye Diseases (WG1)

Subscribe to our mailing list

* indicates required

This ERN is supported by: